Search results
Showing 166 to 180 of 185 results for prostate cancer
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
Discontinued Reference number: GID-TA11252
This guidance has been updated and replaced by NICE technology appraisal guidance 887.
This guidance has been updated and replaced by NICE technology appraisal guidance 1110.
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
We have moved interventional procedures guidance 174 to become HealthTech guidance 113. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE technology appraisal guidance 391.
This guidance has been updated and replaced by NICE guideline CG175.
Read biographies of the members of our quality standards advisory committee.
Read biographies of the members of our quality standards advisory committee.
In development Reference number: GID-TA11443 Expected publication date: TBC
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.